Because of Dr. Folkman's vision, at least 23
different angiogenesis inhibitors have been approved by the FDA for 18 different indications, with 100 different drugs being tested in over 3,000 clinical trials in approximately 43 countries.
Not exact matches
Nintedanib, in addition to blocking vascular endothelial growth factor receptors (VEGFR) and platelet derived growth factor receptors (PDGFR), also acts on fibroblast growth factor receptors (FGFR), which makes it
different to classical
angiogenesis inhibitors.
In the mouse model, treating node metastases with two
angiogenesis inhibitors that have
different mechanisms of action did not change the density of blood vessels or the growth of the metastases.